Canaccord Genuity Initiates Coverage On TriSalus Life Sciences with Buy Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity has initiated coverage on TriSalus Life Sciences (NASDAQ:TLSI) with a Buy rating and set a price target of $12.

May 30, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity has initiated coverage on TriSalus Life Sciences with a Buy rating and a price target of $12, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a price target of $12 by Canaccord Genuity is likely to boost investor confidence and positively impact the stock price of TriSalus Life Sciences in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100